

Maria A Pantaleo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2479797/maria-a-pantaleo-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

147
papers

2,763
citations

28
h-index

46
g-index

157
ext. papers

3,331
ext. citations

5
avg, IF

4.74
L-index

#	Paper	IF	Citations
147	Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 666156	5.7	1
146	Targeted therapy in deficient GIST. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211023278	3.78	4
145	Gene Expression Landscape of SDH-Deficient Gastrointestinal Stromal Tumors. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
144	Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFR/SDH/RAS-P Wild-Type GIST. <i>Frontiers in Oncology</i> , 2020 , 10, 504	5.3	7
143	The Emerging Role of the FGF/FGFR Pathway in Gastrointestinal Stromal Tumor. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	10
142	Letter to the editor concerning "Liver transplantation for metastatic wild-type gastrointestinal stromal tumor in the era of molecular targeted therapies: Report of a first case". <i>American Journal of Transplantation</i> , 2020 , 20, 3701-3702	8.7	
141	Skull Metastasis From Uterine Leiomyosarcoma, a Rare Presentation for a Rare Tumor: A Case Report and Review of the Literature. <i>Frontiers in Oncology</i> , 2020 , 10, 869	5.3	2
140	Diagnostic Accuracy of Cardiac Computed Tomography and 18-F Fluorodeoxyglucose Positron Emission Tomography in Cardiac Masses. <i>JACC: Cardiovascular Imaging</i> , 2020 , 13, 2400-2411	8.4	12
139	Genetic aberrations and molecular biology of cardiac sarcoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920918492	5.4	1
138	Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation. <i>Frontiers in Immunology</i> , 2020 , 11, 851	8.4	6
137	Primary malignant pericardial tumour in Lynch syndrome. <i>BMC Cancer</i> , 2020 , 20, 191	4.8	2
136	Recurrent Uterine Smooth-Muscle Tumors of Uncertain Malignant Potential (STUMP): State of The Art. <i>Anticancer Research</i> , 2020 , 40, 1229-1238	2.3	5
135	The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis. <i>Oncologist</i> , 2020 , 25, e1777-e1784	5.7	10
134	Complete radiological response to first-line regorafenib in a patient with abdominal relapse of mutated GIST. <i>Therapeutic Advances in Gastroenterology</i> , 2020 , 13, 1756284820927305	4.7	1
133	Paratesticular Mesenchymal Malignancies: A Single-Center Case Series, Clinical Management, and Review of Literature. <i>Integrative Cancer Therapies</i> , 2020 , 19, 1534735419900554	3	2
132	Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920936932	5.4	10
131	Living Donor Liver Transplantation for Imatinib-Resistant Gastrointestinal Stromal Tumor Liver Metastases: A New Therapeutic Option in Transplant Oncology. <i>Liver Transplantation</i> , 2020 , 26, 1373-1374	4.5	4

130	Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
129	Gene duplication, rather than epigenetic changes, drives FGF4 overexpression in KIT/PDGFR α /SDH/RAS-P WT GIST. <i>Scientific Reports</i> , 2020 , 10, 19829	4.9	3
128	Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis. <i>Cancers</i> , 2020 , 12,	6.6	7
127	Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile. <i>Cancers</i> , 2020 , 12,	6.6	13
126	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. <i>Cancer</i> , 2020 , 126, 98-104	6.4	14
125	The rs17084733 variant in the 3' UTR disrupts a miR-221/222 binding site in gastrointestinal stromal tumour: a sponge-like mechanism conferring disease susceptibility. <i>Epigenetics</i> , 2019 , 14, 545-557	5.7	7
124	NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas. <i>Journal of Pathology</i> , 2019 , 249, 90-101	9.4	13
123	Gain of FGF4 is a frequent event in KIT/PDGFR α /SDH/RAS-P WT GIST. <i>Genes Chromosomes and Cancer</i> , 2019 , 58, 636-642	5	12
122	Clinical relevance of circulating molecules in cancer: focus on gastrointestinal stromal tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919831902	5.4	13
121	Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response. <i>Onc Immunology</i> , 2019 , 8, e1617588	7.2	20
120	Mechanisms of resistance to a PI3K inhibitor in gastrointestinal stromal tumors: an approach to identify novel druggable targets. <i>Cancer Management and Research</i> , 2019 , 11, 6229-6244	3.6	2
119	Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft. <i>Cancers</i> , 2019 , 11,	6.6	9
118	Current status of the adjuvant therapy in uterine sarcoma: A literature review. <i>World Journal of Clinical Cases</i> , 2019 , 7, 1753-1763	1.6	18
117	Successful multidisciplinary clinical approach and molecular characterization by whole transcriptome sequencing of a cardiac myxofibrosarcoma: A case report. <i>World Journal of Clinical Cases</i> , 2019 , 7, 3018-3026	1.6	2
116	Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 11032-11032	2.2	
115	Molecular modelling evaluation of exon 18 His845_Asn848delinsPro PDGFR α mutation in a metastatic GIST patient responding to imatinib. <i>Scientific Reports</i> , 2019 , 9, 2172	4.9	1
114	Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. <i>Oncologist</i> , 2019 , 24, e536-e541	5.7	12
113	Preferential MGMT methylation could predispose a subset of KIT/PDGFR α -WT GISTs, including SDH-deficient ones, to respond to alkylating agents. <i>Clinical Epigenetics</i> , 2019 , 11, 2	7.7	9

112	Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study. <i>Digestive and Liver Disease</i> , 2019 , 51, 689-694	3.3	18
111	An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor. <i>Pharmacogenomics Journal</i> , 2019 , 19, 390-400	3.5	12
110	Unusual bilateral ovarian metastases from ileal gastrointestinal stromal tumor (GIST): a case report. <i>BMC Cancer</i> , 2018 , 18, 301	4.8	3
109	Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms. <i>Journal of Chemotherapy</i> , 2018 , 30, 53-58	2.3	3
108	Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients. <i>Oncology</i> , 2018 , 94, 7-11	3.6	8
107	Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases. <i>Cancer Communications</i> , 2018 , 38, 41	9.4	4
106	A Single-Centre Experience on the Management of Adenosarcoma: A Successful Report of an Integrated Medical and Surgical Approach. <i>Clinical Medicine Insights: Oncology</i> , 2018 , 12, 1179554918782477	1.8	3
105	Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	19
104	Identification of an Actionable Mutation of KIT in a Case of Extraskeletal Myxoid Chondrosarcoma. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	3
103	Novel intra-genic large deletions of CTNNB1 gene identified in WT desmoid-type fibromatosis. <i>Genes Chromosomes and Cancer</i> , 2018 , 57, 495-503	5	13
102	Immune microenvironment profiling of gastrointestinal stromal tumors (GIST).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11534-11534	2.2	1
101	Characterization of tumor microenvironment in extraskeletal myxoid chondrosarcoma (EMC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11561-11561	2.2	
100	Identification of an actionable mutation of KIT in extraskeletal myxoid chondrosarcoma (EMC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e23547-e23547	2.2	
99	Identification of novel intra-genic deletions of CTNNB1 gene in WT desmoid-type fibromatosis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11577-11577	2.2	
98	Whole Exome Sequencing Uncovers Germline Variants of Cancer-Related Genes in Sporadic Pheochromocytoma. <i>International Journal of Genomics</i> , 2018 , 2018, 6582014	2.5	2
97	F-FDG-PET/CT imaging in cardiac tumors: illustrative clinical cases and review of the literature. <i>Therapeutic Advances in Medical Oncology</i> , 2018 , 10, 1758835918793569	5.4	20
96	Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. <i>Therapeutic Advances in Medical Oncology</i> , 2018 , 10, 1758835918794623	5.4	15
95	Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis. <i>Autophagy</i> , 2017 , 13, 452-463	10.2	36

94	Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST. <i>Molecular Cancer Research</i> , 2017 , 15, 553-562	6.6	34
93	An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure. <i>Angiogenesis</i> , 2017 , 20, 139-148	10.6	8
92	HSPA8 as a novel fusion partner of NR4A3 in extraskeletal myxoid chondrosarcoma. <i>Genes Chromosomes and Cancer</i> , 2017 , 56, 582-586	5	23
91	Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue. <i>Oncotarget</i> , 2017 , 8, 60036-60045	3.3	10
90	The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation. <i>Scientific Reports</i> , 2017 , 7, 11305	4.9	11
89	Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial. <i>Future Oncology</i> , 2017 , 13, 1893-1905	3.6	8
88	The progressive fragmentation of the KIT/PDGFR α wild-type (WT) gastrointestinal stromal tumors (GIST). <i>Journal of Translational Medicine</i> , 2017 , 15, 113	8.5	33
87	Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 484-493	4.3	25
86	Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 731-739	5.4	14
85	Microbiota, NASH, HCC and the potential role of probiotics. <i>Carcinogenesis</i> , 2017 , 38, 231-240	4.6	113
84	What is changing in the surgical treatment of gastrointestinal stromal tumors after multidisciplinary approach? A comprehensive literature's review. <i>Minerva Surgery</i> , 2017 , 72, 219-236	0.1	4
83	Rechallenge in advanced GIST progressing to imatinib, sunitinib and regorafenib: An Italian survey.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11038-11038	2.2	
82	Numerical, dimensional or mixed progression disease to imatinib as prognostic factor in patients with metastatic GIST.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11040-11040	2.2	
81	Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome. <i>Tumor Biology</i> , 2016 , 37, 13413-13423	2.9	17
80	Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. <i>Oncologist</i> , 2016 , 21, 600-7	5.7	20
79	Integrating miRNA and gene expression profiling analysis revealed regulatory networks in gastrointestinal stromal tumors. <i>Epigenomics</i> , 2016 , 8, 1347-1366	4.4	19
78	Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms: A review of the literature and a long-standing experience of a referral center. <i>Digestive and Liver Disease</i> , 2016 , 48, 231-41	3.3	60
77	Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP). <i>Clinical Cancer Research</i> , 2016 , 22, 837-46	12.9	62

76	Sunitinib (SM) in advanced extraskeletal myxoid chondrosarcoma (EMC): Updated analysis in 11 patients (pts).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11059-11059	2.2	1
75	Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. <i>Oncotarget</i> , 2016 , 7, 69412-69419	3.3	10
74	In Reply. <i>Oncologist</i> , 2016 , 21, e5-e6	5.7	
73	Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2016 , 22, 519-33	5.6	50
72	Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors. <i>Anti-Cancer Drugs</i> , 2016 , 27, 353-63	2.4	4
71	Long-term outcome of molecular subgroups of gastrointestinal stromal tumour patients treated with standard-dose imatinib in the BFR14 trial: The wild-type gastrointestinal stromal tumours are not a single group yet. <i>European Journal of Cancer</i> , 2016 , 58, 38-40	7.5	
70	Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial-Mesenchymal Transition-like Process and 22q Loss. <i>Molecular Cancer Research</i> , 2016 , 14, 820-9	6.6	22
69	Gastrointestinal cancer: Management of GIST--go beyond imatinib: treat resistant subtypes. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 440-2	19.4	3
68	Efficacy of weekly docetaxel in locally advanced cardiac angiosarcoma. <i>BMC Research Notes</i> , 2015 , 8, 325	2.3	10
67	miRNA profiling in gastrointestinal stromal tumors: implication as diagnostic and prognostic markers. <i>Epigenomics</i> , 2015 , 7, 1033-49	4.4	22
66	Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. <i>Genetics in Medicine</i> , 2015 , 17, 391-5	8.1	35
65	PDL1 expression is an independent prognostic factor in localized GIST. <i>Oncolmmunology</i> , 2015 , 4, e1002729	7.29	51
64	SDHC methylation in gastrointestinal stromal tumors (GIST): a case report. <i>BMC Medical Genetics</i> , 2015 , 16, 87	2.1	16
63	An immunohistochemical study of potential diagnostic and therapeutic biomarkers of wild-type gastrointestinal stromal tumours. <i>Histopathology</i> , 2015 , 67, 746-7	7.3	1
62	Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 15592-608	6.3	30
61	Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways. <i>Cancer Medicine</i> , 2015 , 4, 101-3	4.8	61
60	Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST). <i>BMC Genomics</i> , 2015 , 16, 892	4.5	37
59	Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome. <i>European Journal of Human Genetics</i> , 2015 , 23, 817-23	5.3	17

58	Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS). <i>Oncotarget</i> , 2015 , 6, 42243-57	3.3	20
57	Discovery of new potentially actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4127-4127	2.2	
56	Metastatic dermatofibrosarcoma protuberans (DFSP) and fibrosarcomatous DFSP (FS-DFSP): Sensitivity to imatinib (IM) and gene expression profile.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 10553-10553	2.2	1
55	Dystrophin deregulation is associated with tumor progression in KIT/PDGFRα mutant gastrointestinal stromal tumors. <i>Clinical Sarcoma Research</i> , 2014 , 4, 9	2.5	7
54	Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRα wild-type GIST. <i>European Journal of Human Genetics</i> , 2014 , 22, 32-9	5.3	74
53	Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours. <i>Oncology Letters</i> , 2014 , 8, 1793-1799	2.6	4
52	Integrated genomic study of quadruple-WT GIST (KIT/PDGFRα/SDH/RAS pathway wild-type GIST). <i>BMC Cancer</i> , 2014 , 14, 685	4.8	61
51	Treatments for gastrointestinal stromal tumors that are resistant to standard therapies. <i>Future Oncology</i> , 2014 , 10, 2045-59	3.6	7
50	Liquid biopsy in gastrointestinal stromal tumors: a novel approach. <i>Journal of Translational Medicine</i> , 2014 , 12, 210	8.5	15
49	Second-line treatment in exon 11-mutated GIST patients: Imatinib dose escalation or sunitinib? Retrospective analysis of a multi-institutional experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10515-10515	2.2	1
48	Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma. <i>World Journal of Gastroenterology</i> , 2014 , 20, 7049-54	5.6	18
47	Integrate whole genomic study of KIT/PDGFRα wild-type (WT) GIST.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10513-10513	2.2	
46	Multicenter retrospective analysis of 31 patients with aggressive angiomyxoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10585-10585	2.2	
45	Insulin-like Growth Factor (IGF) system and gastrointestinal stromal tumours (GIST): present and future. <i>Histology and Histopathology</i> , 2014 , 29, 167-75	1.4	1
44	Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. <i>Clinical Colorectal Cancer</i> , 2013 , 12, 188-94	3.8	21
43	Surgical second-look in high risk gastrointestinal stromal tumor of small intestine: A case report. <i>International Journal of Surgery Case Reports</i> , 2013 , 4, 7-10	0.8	5
42	Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. <i>Pharmacological Research</i> , 2013 , 68, 1-6	10.2	54
41	Expression of IGF-1 receptor in KIT/PDGF receptor-wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction. <i>Future Oncology</i> , 2013 , 9, 121-6	3.6	23

40	An overview on molecular biology of KIT/PDGFR α wild type (WT) gastrointestinal stromal tumours (GIST). <i>Journal of Medical Genetics</i> , 2013 , 50, 653-61	5.8	66
39	Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFR α . <i>Cancer Medicine</i> , 2013 , 2, 21-31	4.8	25
38	Role of molecular analysis in the adjuvant treatment of gastrointestinal stromal tumours: it is time to define it. <i>World Journal of Gastroenterology</i> , 2013 , 19, 2583-6	5.6	2
37	Late recurrences of gastrointestinal stromal tumours (GISTs) after 5 years of follow-up. <i>Medical Oncology</i> , 2012 , 29, 144-50	3.7	6
36	Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. <i>BMC Cancer</i> , 2012 , 12, 231	4.8	32
35	Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice. <i>Targeted Oncology</i> , 2012 , 7, 243-6	5	3
34	Duration of adjuvant treatment following radical resection of metastases from gastrointestinal stromal tumours. <i>Oncology Letters</i> , 2012 , 3, 677-681	2.6	3
33	Development of a Nephrotic Syndrome in a Patient with Gastrointestinal Stromal Tumor during a Long-Time Treatment with Sunitinib. <i>Case Reports in Oncology</i> , 2012 , 5, 651-6	1	5
32	Impressive long-term disease stabilization by nilotinib in two pretreated patients with KIT/PDGFR α wild-type metastatic gastrointestinal stromal tumours. <i>Anti-Cancer Drugs</i> , 2012 , 23, 567-72	2.4	13
31	The follow-up after radical surgery of colorectal cancer: is it time for a "tailored" strategy?. <i>Clinical Colorectal Cancer</i> , 2011 , 10, 81-4	3.8	
30	New molecular targets beyond KIT and PDGFR α in gastrointestinal stromal tumors: present and future. <i>Expert Opinion on Therapeutic Targets</i> , 2011 , 15, 803-15	6.4	1
29	Three cases of bone metastases in patients with gastrointestinal stromal tumors. <i>Rare Tumors</i> , 2011 , 3, e17	1.1	25
28	When should F-18 FDG PET/CT be used instead of 68Ga-DOTA-peptides to investigate metastatic neuroendocrine tumors?. <i>Clinical Nuclear Medicine</i> , 2011 , 36, 1109-11	1.7	4
27	A distinct pediatric-type gastrointestinal stromal tumor in adults: potential role of succinate dehydrogenase subunit A mutations. <i>American Journal of Surgical Pathology</i> , 2011 , 35, 1750-2	6.7	40
26	Differential expression of neural markers in KIT and PDGFR α wild-type gastrointestinal stromal tumours. <i>Histopathology</i> , 2011 , 59, 1071-80	7.3	21
25	The role of mutational analysis of KIT and PDGFR α in gastrointestinal stromal tumors in a clinical setting. <i>Journal of Translational Medicine</i> , 2011 , 9, 75	8.5	36
24	SDHA loss-of-function mutations in KIT-PDGFR α wild-type gastrointestinal stromal tumors identified by massively parallel sequencing. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 983-7	9.7	125
23	Successful radiotherapy for local control of progressively increasing metastasis of gastrointestinal stromal tumor. <i>Rare Tumors</i> , 2011 , 3, e49	1.1	14

22	A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. <i>Laboratory Investigation</i> , 2010 , 90, 1285-94	5.9	71
21	Management of Patients with Gastrointestinal Stromal Tumor in Clinical Practice in Italy: A Critical Event Tree Model—Analysis of Decision-Making Processes and Outcomes. <i>Tumori</i> , 2010 , 96, 219-228	1.7	
20	The emerging role of insulin-like growth factor 1 receptor (IGF1r) in gastrointestinal stromal tumors (GISTs). <i>Journal of Translational Medicine</i> , 2010 , 8, 117	8.5	10
19	Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy. <i>Cancer Treatment Reviews</i> , 2010 , 36, 63-8	14.4	5
18	Preclinical evaluation of KIT/PDGFRα and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010 , 29, 173	12.8	23
17	Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET. <i>Molecular Imaging and Biology</i> , 2010 , 12, 616-25	3.8	16
16	Management of patients with gastrointestinal stromal tumor in clinical practice in Italy: a critical "event tree model" analysis of decision-making processes and outcomes. <i>Tumori</i> , 2010 , 96, 219-28	1.7	
15	Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review). <i>Oncology Reports</i> , 2009 , 21, 1359-66	3.5	45
14	Molecular imaging of EGFR: it's time to go beyond receptor expression. <i>Journal of Nuclear Medicine</i> , 2009 , 50, 1195-6; author reply 1196, 1197	8.9	6
13	MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. <i>Experimental Cell Research</i> , 2009 , 315, 1439-47	4.2	207
12	Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. <i>International Journal of Cancer</i> , 2009 , 125, 2991-4	7.5	66
11	To widen the setting of cancer patients who could benefit from metronomic capecitabine. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 189-93	3.5	14
10	Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. <i>Cancer Treatment Reviews</i> , 2009 , 35, 201-9	14.4	119
9	Unusual finding of benign Abrikossoff tumor by F-18 FDG-PET mimicking melanoma recurrence. <i>Clinical Nuclear Medicine</i> , 2009 , 34, 696-7	1.7	4
8	Gastrointestinal stromal tumors: report of an audit and review of the literature. <i>European Journal of Cancer Prevention</i> , 2009 , 18, 106-16	2	39
7	¹¹ C-Acetate PET for Early Prediction of Sunitinib Response in Metastatic Renal Cell Carcinoma. <i>Tumori</i> , 2009 , 95, 382-384	1.7	27
6	Activated NF-κB in colorectal cancer: predictive or prognostic factor?. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1388-9; author reply 1389-90	2.2	13
5	Intestinal microflora and digestive toxicity of irinotecan in mice. <i>Clinical Cancer Research</i> , 2006 , 12, 1299-307	11.7	63

4	Cardiac metastasis of melanoma. <i>Melanoma Research</i> , 2005 , 15, 315-6	3.3	4
3	Risk of duodenal adenomas in familial adenomatous polyposis to progress toward advanced neoplastic disease. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3835-6; author reply 3836-7	2.2	1
2	Spontaneous regression of a desmoid intraabdominal tumor in a patient affected by familial adenomatous polyposis. <i>American Journal of Gastroenterology</i> , 2004 , 99, 1621-2	0.7	2
1	Treatment of brain metastases of malignant melanoma with temozolomide. <i>New England Journal of Medicine</i> , 2001 , 345, 621-2	59.2	62